Sector Expert: Jason Napodano

Image: Jason Napodano

Jason Napodano of BioNap Consulting formerly worked for Zacks Investment Research as the company's senior biotechnology analyst. Prior to his tenure at Zacks, Napodano spent three years on the buyside with Eastover Capital in Charlotte, N.C., where he focused on large-cap equities and specialized in healthcare, energy and technology. Prior to joining Eastover, Napodano worked as a research scientist for TechLab Inc., a biotechnology company focused on developing diagnostic kits and vaccines for infectious diseases. He also spent a year working in a lab at the Fralin Biotechnology Center, and a year working for a cancer researcher in Virginia. Napodano has a bachelor's degree in biochemistry from Virginia Tech and a master's degree in business administration and finance, with a concentration in securities analysis, from Wake Forest University. Napodano is also a Chartered Financial Analyst (CFA).



Recent Interviews

Let Your Biotech Winners Ride into Orbit: Jason Napodano of BioNap Consulting (12/16/15)
goldpill630

Before starting his own firm in July, Jason Napodano spent more than 12 years at Zacks Investment Research producing highly detailed small-cap biotechnology research. Today, as owner and senior analyst at BioNap Consulting, Napodano is doing much the same, but with more flexibility. He follows dozens of companies and continues to perform diligence on new names with the single goal of finding multibaggers. One of his themes is to take a biotech basket-of-stocks approach, since he knows some names will fail but the winners will move upward with momentum. In this interview with The Life Sciences Report, Napodano discusses small-cap names with the potential to power portfolios to extraordinary levels.

Zacks' Jason Napodano Is Not Focused on a Biotech Bubble (7/8/15)
drugmoney580

It's all about the fundamentals for Jason Napodano, CFA, of Zacks Investment Research. Revenue and earnings at the big biotechs are signaling investors that the market is still strong, and that there is still a huge thirst for early-stage devices, small molecules, biologics and cellular therapies. In this interview with The Life Sciences Report, Napodano details the upside for small-cap biotech names that he believes will be huge gainers for investor portfolios.

Off to the Races with Seven Extraordinary Biotech and Medtech Companies: Jason Napodano (8/1/13)

Senior Biotechnology Analyst Jason Napodano of Zacks Investment Research specializes in uncovering small biotech and medtech companies with good prospects for successful drug development. He relishes proven management capable of creative financing to move private equity into the public markets, and he does not shy away from tiny companies outside the U.S. that have extraordinary technology. In this wide-ranging interview with The Life Sciences Report, Napodano presents the elegant growth stories of seven small companies that could return magnificent gains to investors.

Recent Quotes

"BOTA is well funded and has lots of clinical catalysts coming in 2016."

The Life Sciences Report Interview with Jason Napodano (12/16/15)
more >

"RNN has three very interesting, early-stage anticancer drugs, and a sound development program."

The Life Sciences Report Interview with Jason Napodano (12/16/15)
more >

"BCT is early stage right now, but I really like the science."

The Life Sciences Report Interview with Jason Napodano (12/16/15)
more >

"CANF had big potential in its clinical pipeline and an incredibly cheap valuation."

The Life Sciences Report Interview with Jason Napodano (12/16/15)
more >

"If results from RVX's Phase 3 program are positive, the stock could have a significant revaluation to much higher levels."

The Life Sciences Report Interview with Jason Napodano (7/8/15)
more >

"CYNA is now well funded, NASDAQ-listed and liquid; it isdefinitely among my better ideas as of today."

The Life Sciences Report Interview with Jason Napodano (7/8/15)
more >

"I think a large pharma company would be very interested in CTRV's FV-100."

The Life Sciences Report Interview with Jason Napodano (7/8/15)
more >

"BCLI has what looks to be a safe and potentially effective treatment for delaying disease progression in patients with ALS."

The Life Sciences Report Interview with Jason Napodano (7/8/15)
more >

more comments

"Signs point to fundamental strength for CTH."

— Jason Napodano, Zacks Small-Cap Research (6/22/15)
more >

"For all indications, we estimate CANF will sign partnership agreements."

— Jason Napodano, Zacks Small-Cap Research (6/2/15)
more >

"Efficacy of CANF's CF101 in psoriasis is similar to Celgene's Otezla."

— Jason Napodano, Seeking Alpha (4/29/15)
more >

"RVX is addressing the major unmet medical need of cardiovascular management."

— Jason Napodano, Zacks Equity Research (4/20/15)
more >

"BCLI has a favorable risk/reward profile and tremendous upside for Nur-Own."

— Jason Napodano, Seeking Alpha (4/13/15)
more >

"CTH will conduct a short bridging study, CTH-200, to start in Q2/15."

— Jason Napodano, Zacks Small-Cap Research (3/18/15)
more >

"We are initiating coverage of RESX."

— Jason Napodano, Zacks Small-Cap Research (3/16/15)
more >

— Jason Napodano, Zacks Small-Cap Research (3/9/15)
more >

"CTH's stock still represents an attractive opportunity for investors."

— Jason Napodano, Zacks Investment Research (1/5/15)
more >

"Results from the Phase 2 study due in Q1/15 could double CUR's stock."

— Jason Napodano, Zacks Investment Research (1/5/15)
more >

"Data from CUR's Phase 2 ALS study are expected during Q1/15."

— Jason Napodano, Zacks Small-Cap Research (11/7/14)
more >

"With 5% U.S. market share, CUR's NSI-566 is a potential $500M drug."

— Jason Napodano, Seeking Alpha (10/15/14)
more >

"IMNP has enormous upside potential; it is one of our top ideas."

— Jason Napodano, Zacks Small-Cap Research (8/25/14)
more >

"CUR has enough cash to fund operations into the middle of 2016."

— Jason Napodano, Zacks Small-Cap Research (8/8/14)
more >

"A rapid and economical test like AMBS' LymPro could be used to improve Alzheimer's patient enrollment for future clinical trials."

— Jason Napodano, Seeking Alpha (8/6/14)
more >

"IMNP is an undiscovered gem that could triple in value over the next several months."

— Jason Napodano, Zacks Small-Cap Research (7/8/14)
more >

"We continue to be optimistic on the future of CUR."

— Jason Napodano, Zacks Small-Cap Research (6/25/14)
more >

"We believe CTH's APL-130277 is a potential $700M product."

— Jason Napodano, Seeking Alpha (5/29/14)
more >

"IMNP significantly improved its balance sheet in Q1/14 and is nearing a partnership transaction."

— Jason Napodano, Zacks Small-Cap Research (5/28/14)
more >

"We feel confident that BLU's Phase 3 trial for Kiacta will be successful."

— Jason Napodano, Seeking Alpha (5/20/14)
more >

"CTH shares offer a potential sixfold increase in returns."

— Jason Napodano, Zacks Small-Cap Research (5/8/14)
more >

"AMBS now has the financial resources to drive its assets forward."

— Jason Napodano, Zacks Small-Cap Research (4/25/14)
more >

"NSI-566 in amyotrophic lateral sclerosis and spinal cord injury alone make CUR an attractive investment."

— Jason Napodano, Seeking Alpha (4/21/14)
more >

"CTH has huge upside, a clear exit strategy and a drug that works."

— Jason Napodano, Seeking Alpha (4/16/14)
more >

"CTH shares offer a potential sixfold increase in returns."

— Jason Napodano, Zacks Small-Cap Research (3/28/14)
more >

"CUR continues on track with development of its lead compounds and has raised significant amounts of cash recently."

— Jason Napodano, Zacks Small-Cap Research (3/11/14)
more >

"AMBS will exercise outstanding warrants that will deliver +$3M."

— Jason Napodano, Seeking Alpha (2/18/14)
more >

"There is a lot to be encouraged by from CUR's phase 1 trial data."

— Jason Napodano, Seeking Alpha (2/17/14)
more >

"CTH is one of our best ideas in the small-cap biotechnology sector."

— Jason Napodano, Seeking Alpha (2/11/14)
more >

fewer comments


Due to permission requirements, not all quotes are shown.